GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange Disclosure under Regulation 30(5) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals has informed the stock exchanges about the personnel authorized to determine materiality of events for disclosure purposes, as required under SEBI regulations. The company has jointly authorized four senior officials: the Managing Director (Bhushan Akshikar), Whole-time Director & CFO (Ronojit Biswas), Company Secretary (Ajay Nadkarni), and Head of Legal (Amit Pandey). This is a routine regulatory compliance filing under Regulation 30(5) of the SEBI Listing Obligations and Disclosure Requirements. The disclosure was made on 21st April 2026 and has been signed by Ajay Nadkarni, Vice President and Company Secretary.
This filing has no direct impact on the company's financials or stock price as it is purely administrative. It simply updates the stock exchanges on internal authorization for disclosure decisions, a standard compliance requirement.